Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Adult Solid Neoplasm 1

Interventions

temsirolimus 1ixabepilone 1Vorinostat 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Erlotinib Hydrochloride 1Epothilones 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adult Solid Neoplasm × Erlotinib Hydrochloride × Clear all
NCT00045201 2026-04-13

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
60 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡